ResearcherColumbia UniversityActive in the last 2 years
Benjamin Izar
Matched on ORCID iD 0000-0003-2379-6702; OpenAlex author ID A5052100404. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 20
2025: 1 paper · 2026: 2 papers
Papers 3
- Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives. Co-author DOI 10.1038/s41467-026-76559-4↗
- Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO. Co-author DOI 10.1200/po-26-00138↗
- Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41588-025-02345-5↗
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Michael S. May · 3 shared papers, 2025–2026 · strength 0.57
- Paper Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Cl… DOI 10.1200/po-26-00138↗
- Paper Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study w… DOI 10.1038/s41467-026-76559-4↗
- Paper Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma. DOI 10.1038/s41588-025-02345-5↗
- Alexander Grenander Raufi · 3 shared papers, 2025–2026 · strength 0.57
- Paper Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Cl… DOI 10.1200/po-26-00138↗
- Paper Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study w… DOI 10.1038/s41467-026-76559-4↗
- Paper Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma. DOI 10.1038/s41588-025-02345-5↗
- Gulam Abbas Manji · 3 shared papers, 2025–2026 · strength 0.57
- Paper Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Cl… DOI 10.1200/po-26-00138↗
- Paper Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study w… DOI 10.1038/s41467-026-76559-4↗
- Paper Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma. DOI 10.1038/s41588-025-02345-5↗
- Alina Cornelia Iuga · 2 shared papers, 2026 · strength 0.39
- Paper Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Cl… DOI 10.1200/po-26-00138↗
- Paper Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study w… DOI 10.1038/s41467-026-76559-4↗
- Susan Elaine Bates · 2 shared papers, 2026 · strength 0.39
- Paper Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Cl… DOI 10.1200/po-26-00138↗
- Paper Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study w… DOI 10.1038/s41467-026-76559-4↗
- Linda Y. Wu · 2 shared papers, 2026 · strength 0.39
- Paper Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Cl… DOI 10.1200/po-26-00138↗
- Paper Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study w… DOI 10.1038/s41467-026-76559-4↗
- Kenneth P. Olive · 2 shared papers, 2026 · strength 0.39
- Paper Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Cl… DOI 10.1200/po-26-00138↗
- Paper Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study w… DOI 10.1038/s41467-026-76559-4↗
- Michael D. Kluger · 2 shared papers, 2025–2026 · strength 0.37
- Paper Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study w… DOI 10.1038/s41467-026-76559-4↗
- Paper Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma. DOI 10.1038/s41588-025-02345-5↗
- John A. Chabot · 2 shared papers, 2025–2026 · strength 0.37
- Paper Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study w… DOI 10.1038/s41467-026-76559-4↗
- Paper Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma. DOI 10.1038/s41588-025-02345-5↗
- Emanuel F. Petricoin · 1 shared paper, 2026 · strength 0.20
- Brian William Labadie · 1 shared paper, 2026 · strength 0.20
- Andrea Califano · 1 shared paper, 2026 · strength 0.20
- Urszula N. Wasko · 1 shared paper, 2026 · strength 0.20
- Howard P. Safran · 1 shared paper, 2026 · strength 0.20
- Li Li · 1 shared paper, 2026 · strength 0.19
- Beth Schrope · 1 shared paper, 2026 · strength 0.19
- Tito Fojo · 1 shared paper, 2026 · strength 0.19
- Morteza Chalabi Hajkarim · 1 shared paper, 2025 · strength 0.18
- Jacob K.R. Jamison · 1 shared paper, 2025 · strength 0.18
- Basil S. Bakir · 1 shared paper, 2025 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.